Jump to Navigation

Meridia Fact Sheet

Printer-friendly version
Medication Name (brand): 
Meridia
Medication Name (clinical): 
sibutramine
Manufacturer: 

Abbott

Indications: 

FDA approved 1997 for the treatment of obesity.

Mechanism: 

Works by inhibiting the reuptake of both norepinephrine and serotonin, thereby suppressing appetite.

Dosing: 
  • Supplied as 5 mg, 10 mg, and 15 mg capsules (not breakable).

  • Start with 10 mg QD, titrate up to 15 mg QD if weight loss isn’t adequate.
  • No dosage adjustment required in mild to moderate renal or hepatic impairment.

Evidence of Efficacy: 

One of the most effective weight loss agents, leading to 10 lbs. more weight loss than placebo over one year follow-up, according to meta-analyses.

Side Effects: 
  • Common: Headache, insomnia, dry mouth, constipation.

  • Increased BP and heart rate; should not be used in patients with heart disease.

Drug-drug Interactions: 
  • Since Meridia is a dual reuptake inhibitor, the manufacturer advises that it not be combined with other serotonin or dual reuptake inhibitors, because of a theoretical concern of serotonin syndrome.

  • Contraindicated with MAOIs.
  • Contraindicated for patients with anorexia or bulimia nervosa.

Pharmokinetics: 
  • Metabolized to active metabolites (M1 and M2) by CYP 3A4, which are further metabolized by conjugation and hydroxylation.

  • Half-life about 15 hours.

Return to issue area